Search All News
Only select neurons die during Parkinson’s disease. Columbia researchers are looking for clues in immune cells to find out what makes these brain cells so vulnerable.
With several targeted Parkinson’s disease drugs entering clinical trials, a new genetic testing and counseling program may help identify patients who qualify for enrollment.
Columbia neurologists and engineers are using a robotic device to investigate how Parkinson’s affects the ability to walk and respond to balance perturbations.
Researchers have found the first direct evidence that autoimmunity plays a role in Parkinson’s disease.
- May 3, 2017
Columbia scientists observed how molecules that regulate chemical signaling in the brain interact with the AMPA receptor, governing brain function.
- December 21, 2015
A drug that boosts activity in the brain’s “garbage disposal” system can decrease levels of toxic proteins associated with Alzheimer’s disease.
- June 9, 2014
A new study measures the risk of developing Parkinson's for people with Gaucher disease and Gaucher carriers.
- April 30, 2014
Researchers have identified two types of neurons that enable the spinal cord to control skilled forelimb movement. The findings could lead to new ways to treat movement disorders.
- April 7, 2014
Scientists studying Parkinson's disease rely on the generous donation of brains by patients—as well as some family members—to brain banks.
- March 18, 2013
Study finds tiny, targeted drug particles may be effective in treating chronic diseases
- March 5, 2013
Scientists discovered how common genetic mutations in Parkinson’s disease damage brain cells
- December 5, 2012
A new genetic test, microarray, found significantly more clinically relevant information than the standard method - results in NEJM.
- December 8, 2004
Columbia University Medical Center part of multi-center trial that may resolve controversy over most effective Parkinson therapy.